Clinical Consultations™: SARS-CoV-2 Vaccination in Patients with MS – What Clinicians Need to Know Now

Release Date: June 29, 2021

Expiration Date: June 29, 2022

Activity Overview

This Clinical Consultations™ is a video-based program in which two experts discuss the management of patients with multiple sclerosis (MS) and SARS-CoV-2 vaccinations. In this activity, the faculty focus on the effects of disease modifying therapies (DMTs) on vaccine practices, specifically the mRNA vaccines for SARS-CoV-2. This engaging format is designed to help clinicians identify best practices in the management of patients with MS and to improve outcomes for their patients with this disease in the era of COVID-19.

There are over a dozen FDA-approved DMTs to treat patients with MS. These therapies have various effects on humoral and cellular immunity, which are the key components in the protective immune response generated by vaccinations. In the midst of the COVID-19 pandemic, several mRNA-based vaccines for SARS-CoV-2 have been developed. Their effectiveness is based in part on the cell-mediated adaptive immune response. It is this cell-mediated response to vaccines that is of particular importance to clinicians who manage patients with MS, as patients who are treated with DMTs face challenges with respect to the interaction between DMTs that affect the humoral immune response and vaccines in general.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

This activity is jointly provided by Physicians’ Education Resource®, LLC and the Consortium of Multiple Sclerosis Centers.

Target Audience

This activity is intended for community neurologists, MS specialists, specialty NPs, PAs, RNs, pharmacists and other members of the MS care team.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Discuss the effects of vaccines on the immune response
  • Outline the mechanisms of action of vaccines targeting SARS-CoV-2
  • Describe the impact of disease modifying therapies used in the management of MS on response to vaccines
  • Incorporate evidence-based SARS-CoV-2 vaccination strategies into disease management plans for patients with MS

Faculty

Amit Bar-Or, MD, FRCPC
Melissa and Paul Anderson Chair
Professor of Neurology
Director, Center for Neuroinflammation and Experimental Therapeutics
Chief, Division of MS and Related Disorders
University of Pennsylvania
Philadelphia, PA

Fred D. Lublin, MD
Saunders Family Professor of Neurology
Director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Icahn School of Medicine
Mount Sinai
New York, New York

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.25 Contact Hours.

In support of improving patient care, the Consortium of Multiple Sclerosis Centers (CMSC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This knowledge-based activity (UAN #JA4008165-9999-21-009-H01-P) qualifies for 1.25 contact hours (.125 CEUs) of continuing pharmacy education credit.

 

About Me

The Continuing Medical Education Program is an integral part of the organization’s overall mission which aims to improve learners’ competence and performance‐in‐practice and ultimately improve patient outcomes.

Related Posts